Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, February 24, 2023
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
Raghuram Selvaraju Reiterated (ACRS) at Strong Buy and Held Target at $50 on, Feb 24th, 2023
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "Aclaris Therapeutics, Inc." (ACRS) at Strong Buy and Held Target at $50 on, Feb 24th, 2023.
Raghuram has made no other calls on ACRS in the last 4 months.
There are 3 other peers that have a rating on ACRS. Out of the 3 peers that are also analyzing ACRS, 0 agree with Raghuram's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Raghuram
- Louise Chen of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $38 on, Tuesday, February 7th, 2023
- Alex Thompson of "Stifel" Initiated at Strong Buy and Held Target at $29 on, Wednesday, December 14th, 2022
- Corinne Jenkins of "Goldman Sachs" Initiated at Strong Buy and Held Target at $25 on, Thursday, December 1st, 2022
